Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:TORC

resTORbio (TORC) Stock Price, News & Analysis

resTORbio logo

About resTORbio Stock (NASDAQ:TORC)

Key Stats

Today's Range
$1.20
$1.30
50-Day Range
$2.28
$14.77
52-Week Range
$0.86
$10.50
Volume
477,366 shs
Average Volume
1.15 million shs
Market Capitalization
$45.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Adicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Receive TORC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for resTORbio and its competitors with MarketBeat's FREE daily newsletter.

TORC Stock News Headlines

Adicet Bio Inc (ACET)
The Final Frontier
And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.
TinOne Resources Inc. (TORC.V)
See More Headlines

TORC Stock Analysis - Frequently Asked Questions

resTORbio, Inc. (NASDAQ:TORC) released its quarterly earnings results on Thursday, July, 30th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.07.

resTORbio (TORC) raised $86 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 5,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that resTORbio investors own include Novavax (NVAX), VBI Vaccines (VBIV), AbbVie (ABBV), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and CRISPR Therapeutics (CRSP).

Company Calendar

Last Earnings
7/30/2020
Today
11/05/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TORC
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-82,740,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.24 per share

Miscellaneous

Free Float
N/A
Market Cap
$45.93 million
Optionable
Not Optionable
Beta
2.43
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:TORC) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners